Paula M. Fracasso

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Kwok-K. Wong, Paula M. Fracasso, Ronald M. Bukowski et al. · Clinical Cancer Research · 2009 · 302 citations · Full text

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

Rebecca Aft, Michael Naughton, Kathryn Trinkaus et al. · The Lancet Oncology · 2010 · 270 citations · Full text

Zoledronic Acid, Breast Oncology, Open Label +7

Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.

Joanne Mortimer, Farrokh Dehdashti, Barry A. Siegel et al. · PubMed · 1996 · 200 citations

Positron Emission Tomography, Breast Oncology, Medicine +14

Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.

Susan R. Keyes, Paula M. Fracasso, David Heimbrook et al. · PubMed · 1984 · 177 citations

Chemoprevention Strategy, Mitomycin C1, Molecular Biology +23

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

David S. Hong, Brian A. Van Tine, Swethajit Biswas et al. · Nature Medicine · 2023 · 171 citations · Full text